{"disease":{"id":"unresectable-stage-iii-nsclc","name":"unresectable stage iii nsclc"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"chembl-chembl3301587","indication_name":"Unresectable Stage III NSCLC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":50,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05887011","title":"CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04161352","title":"Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT06635824","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":191,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT04381494","title":"Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04982549","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}